683 Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

683 Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23M	Sell	1,279,512 -250,488	-16%	-$3.87M	1.13%	23
2026 Q1	$21.3M	Sell	1,530,000 -120,000	-7%	-$1.69M	1.11%	19
2025 Q4	$19.9M	Sell	1,650,000 -110,000	-6%	-$1.49M	0.87%	24
2025 Q3	$23.9M	Sell	1,760,000 -400,000	-19%	-$3.76M	1.25%	23
2025 Q2	$13.8M	Sell	2,160,000 -251,400	-10%	-$1.22M	0.91%	28
2025 Q1	$8.54M	Buy	2,411,400 +481,400	+25%	+$1.71M	0.59%	50
2024 Q4	$7.3M	Sell	1,930,000 -70,000	-4%	-$329K	0.45%	53
2024 Q3	$6.48M	Buy	2,000,000 +498,129	+33%	+$1.12M	0.49%	53
2024 Q2	$2.85M	Buy	+1,501,871	New	+$2.91M	0.22%	79
2022 Q3	–	Sell	-677,714	Closed	-$13M	–	242
2022 Q2	$13M	Hold	677,714	–	–	0.92%	35
2022 Q1	$7.68M	Buy	+677,714	New	+$15.3M	0.41%	65

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

683 Capital Management's AMLX Position: Q2 2026 in Review

683 Capital Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 16% in Q2 2026, selling an estimated $3.87M and leaving 1,279,512 shares worth $23M. The position accounts for 1.13% of the portfolio, ranked #23.

683 Capital Management first reported a position in AMLX in Q1 2022 and has held it in 11 quarters since. The position peaked at $23.9M in Q3 2025. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

683 Capital Management held 1,279,512 shares of Amylyx Pharmaceuticals worth $23M as of Q2 2026.
683 Capital Management sold 250,488 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $3.87M.
Amylyx Pharmaceuticals made up 1.13% of 683 Capital Management's portfolio in Q2 2026, its #23 holding.
683 Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
683 Capital Management's Amylyx Pharmaceuticals position peaked at $23.9M in Q3 2025.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.